CStone Pharmaceuticals Co., Ltd. (09966) intends to allocate a total of 14.6 million existing shares by its controlling shareholder, Rubymab Ltd.

Wisdom Financial News APP, Kangning Jeri Pharmaceuticals-B (09966) announced that on June 2, 2025, the board of directors of the company was informed by one of the company's controlling shareholders, Rubymab Ltd. (the seller), that they have entered into a share sale agreement with Morgan Stanley & Co. International plc (the exclusive placement agent). The exclusive placement agent has agreed to act as the seller's agent to facilitate the buyer's purchase of a total of 14.6 million shares of the company's existing shares held by Rubymab Ltd. (shares)(representing approximately 1.51% of the total issued share capital of the company as of the date of this announcement) at a price of HK$8.05 per share. If unsuccessful, the exclusive placement agent will purchase the shares on its own (placement matter).